Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 17/20 | 0.66 |
| ▸ | IMPDH1 | P20839 | 7/20 | 0.64 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1475401 | 0.87 | IMPDH2 (0.75) | IMPDH2IMPDH1AAK1HDAC3HDAC4 | |
| SCHEMBL1473844 | 0.87 | IMPDH2 (0.75) | IMPDH2IMPDH1AAK1HDAC3HDAC4 | |
| SCHEMBL1473370 | 0.86 | IMPDH2 (0.73) | IMPDH2IMPDH1AAK1HDAC3HDAC4 | |
| SCHEMBL1473171 | 0.86 | IMPDH2 (0.73) | IMPDH2IMPDH1AAK1HDAC3HDAC4 | |
| SCHEMBL1473702 | 0.86 | IMPDH2 (0.66) | IMPDH2IMPDH1AAK1HDAC3HDAC4 | |
| SCHEMBL1475877 | 0.85 | IMPDH2 (0.69) | IMPDH2IMPDH1AAK1HDAC3HDAC4 | |
| SCHEMBL6490216 | 0.82 | IMPDH2 (0.81) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL5867250 | 0.82 | QPCT (0.45) | IMPDH2IMPDH1 | |
| SCHEMBL1474061 | 0.81 | IMPDH2 (0.64) | IMPDH2IMPDH1AAK1HDAC3HDAC4 | |
| SCHEMBL1474388 | 0.81 | IMPDH2 (0.61) | IMPDH2IMPDH1AAK1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7060720-B2 | Inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB CO. (US) | 2006-06-13 | — | — | US | claimed |
| US-7915255-B2 | Metabolism-modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2011-03-29 | — | — | US | disclosed |
| US-7205324-B2 | Inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-20060122245-A1 | Novel inhibitors of IMPDH enzyme | GU HENRY H | 2006-06-08 | — | — | US | disclosed |
| US-7053111-B2 | Inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB CO. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060106097-A1 | Metabolism-modulating agents and uses therefor | UNIVERSITY OF QUEENSLAND (AU) | 2006-05-18 | — | — | US | disclosed |
| US-6624184-B1 | Identification of the inhibitors of IMPDH (inosine-5'-monophosphate dehydrogenase). The compounds and pharmaceutical compositions disclosed herein are useful in treating or preventing IMPDH associated disorders, and | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122245-A1 | Novel inhibitors of IMPDH enzyme | IMPDH1, IMPDH2, IMPA1 | IMPDH2 2/4885IMPDH1 1/4885AAK1 1956/4885 |
| US-20060106097-A1 | Metabolism-modulating agents and uses therefor | IMPDH1, IMPDH2, HADHB | IMPDH2 2/4885IMPDH1 1/4885AAK1 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.